​
​

Forte Biosciences Stock (NASDAQ:FBRX)

RevenueOwnershipFinancialsChart
Forte Biosciences by TradingView

Previous Close

$7.11

52W Range

$6.50 - $21.55

50D Avg

$11.02

200D Avg

$15.19

Market Cap

$10.63M

Avg Vol (3M)

$4.89K

Beta

1.45

Div Yield

-

FBRX Company Profile

Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

11

IPO Date

Apr 13, 2017

Website

FBRX Performance

FBRX Financial Summary

Dec 23Dec 22Dec 21
Revenue---
Operating Income$-32.49M$-13.90M$-21.49M
Net Income$-31.48M$-13.86M$-21.71M
EBITDA$-32.49M$-13.90M$-21.45M
Basic EPS-$-0.80$-1.55
Diluted EPS-$-0.80$-1.55

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts

Q1 21May 11, 21 | 7:24 AM

Peer Comparison

TickerCompany
DBTXDecibel Therapeutics, Inc.
ABVCABVC BioPharma, Inc.
EWTXEdgewise Therapeutics, Inc.
KTTAPasithea Therapeutics Corp.
ERASErasca, Inc.
CCCCC4 Therapeutics, Inc.
RZLTRezolute, Inc.
HOWLWerewolf Therapeutics, Inc.
INDPIndaptus Therapeutics, Inc.
TPSTTempest Therapeutics, Inc.
CELCCelcuity Inc.